Competitive landscape and policy backdrop
Zepbound competes directly with Novo Nordisk’s Wegovy and Ozempic, both of which have also faced price adjustments as the two companies vie for market share. Novo Nordisk has been trimming prices after ceding ground to Lilly in recent quarters. Sector analysts note that additional price pressure was anticipated for 2024 under an agreement the two manufacturers reached with the previous U.S. administration on GLP-1 products.
While cheaper list prices will initially dampen revenue per unit, Lilly and its followers argue that the affordability improvement should bring in new patients and ultimately raise overall sales volumes. The obesity therapeutics segment has been expanding rapidly, in part because the drugs have shown significant weight-loss benefits in clinical trials, leading some observers, including the U.S. Food and Drug Administration, to identify them as a breakthrough option for certain patients.
Market reaction and broader equity trends
Eli Lilly shares slipped roughly 1% in afternoon trading after the announcement, tracking a modest pullback across major U.S. indexes. The S&P 500 edged lower on the session, giving back a portion of the nearly 4% advance recorded during Thanksgiving week that pushed the benchmark into positive territory for November and marked its seventh consecutive monthly gain. The Nasdaq Composite also dipped after rising more than 4% last week; the tech-heavy index still finished November down 1.5%, ending its own seven-month winning streak.
Analyst outlook on earnings
Wall Street firms monitoring Eli Lilly maintain that any reduction in near-term revenue per dose is likely to be offset by accelerating demand. Consensus forecasts point to sustained double-digit earnings-per-share growth over the next several years as obesity and diabetes products—Zepbound, Mounjaro and partnered formulations—extend their reach.
Leerink stated Monday that the company’s pricing decision should not surprise investors familiar with the regulatory discussions and competitive dynamics in the GLP-1 class. The brokerage expects Lilly to continue capturing share from Novo Nordisk even under lower average selling prices, citing manufacturing scale, supply reliability and physician enthusiasm for newer dosing regimens.
Imagem: Internet
Deal activity in the financial sector
Elsewhere on Monday, Goldman Sachs said it will acquire Innovator Capital Management, a specialist in defined-outcome exchange-traded funds, for $2 billion. Innovator launched the first so-called buffer ETF in 2018 and manages $28 billion in assets. The products use options strategies to provide a predetermined upside cap while cushioning initial losses over a stated period, thereby appealing to investors seeking controlled equity exposure.
Goldman believes the purchase will expand its asset-management division’s ETF lineup and accelerate growth in one of the fastest-growing active ETF categories. The bank has pursued several deals this year aimed at bolstering its asset and wealth management franchise, including a September agreement with T. Rowe Price to develop private-market offerings.
Upcoming earnings
Investors will receive additional data points this week from several corporate reports. MongoDB is scheduled to announce quarterly results after Monday’s closing bell. United Natural Foods and Signet Jewelers are due to report before Tuesday’s market open. Performance from these firms could offer insight into software demand, grocery distribution trends and discretionary retail spending ahead of the holiday period.
Market participants also continue to monitor macroeconomic indicators due later in the week, including updates on job openings, private-sector employment and consumer sentiment, which may influence expectations for Federal Reserve policy into the new year.
Crédito da imagem: CNBC
